Literature DB >> 24468677

Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.

S Saturni1, F Bellini1, F Braido2, P Paggiaro3, A Sanduzzi4, N Scichilone5, P A Santus6, L Morandi1, A Papi7.   

Abstract

Randomized Controlled Trials (RCTs) are the "gold standard" for evaluating treatment outcomes providing information on treatments "efficacy". They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the "effectiveness" of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real life trials have high generalizability, but low internal validity. Recently the number of real life studies has been rapidly growing in different areas of respiratory medicine, particularly in asthma and COPD. The role of such studies is becoming a hot topic in respiratory medicine, attracting research interest and debate. In the first part of this review we discuss some of the advantages and disadvantages of different types of RCTs and analyze the strengths and weaknesses of real life trials, considering the recent examples of some studies conducted in COPD. We then discuss methodological approaches and options to overcome some of the limitations of real life studies. Comparing the conclusions of effectiveness and efficacy trials can provide important pieces of information. Indeed, these approaches can result complementary, and they can guide the interpretation of each other results.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; COPD; Randomized controlled trials; Real life studies

Mesh:

Year:  2014        PMID: 24468677     DOI: 10.1016/j.pupt.2014.01.005

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  52 in total

1.  Randomized controlled clinical trials versus real-life atrial fibrillation patients treated with oral anticoagulants. Do we treat the same patients?

Authors:  Paweł Balsam; Agata Tymińska; Krzysztof Ozierański; Martyna Zaleska; Katarzyna Żukowska; Katarzyna Szepietowska; Kacper Maciejewski; Michał Peller; Marcin Grabowski; Piotr Lodziński; Łukasz Kołtowski; Anna Praska-Ogińska; Inna Zaboyska; Janusz Bednarski; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Cardiol J       Date:  2018-11-08       Impact factor: 2.737

2.  Testing the concurrent validity of a naturalistic upper extremity reaching task.

Authors:  S Y Schaefer; C R Hengge
Journal:  Exp Brain Res       Date:  2015-10-05       Impact factor: 1.972

3.  Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.

Authors:  Peter M Ten Klooster; Martijn A H Oude Voshaar; Walid Fakhouri; Inmaculada de la Torre; Claudia Nicolay; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

4.  Q-Finder: An Algorithm for Credible Subgroup Discovery in Clinical Data Analysis - An Application to the International Diabetes Management Practice Study.

Authors:  Cyril Esnault; May-Line Gadonna; Maxence Queyrel; Alexandre Templier; Jean-Daniel Zucker
Journal:  Front Artif Intell       Date:  2020-12-17

Review 5.  Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.

Authors:  Neeraj Narula; John K Marshall; Jean-Frederic Colombel; Grigorios I Leontiadis; John G Williams; Zack Muqtadir; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

6.  Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.

Authors:  Maddalena Napolitano; Luisa Costa; Francesco Caso; Matteo Megna; Raffaele Scarpa; Nicola Balato; Fabio Ayala; Anna Balato
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

7.  Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer.

Authors:  Bonny Parkinson; Rosalie Viney; Marion Haas; Stephen Goodall; Preeyaporn Srasuebkul; Sallie-Anne Pearson
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

8.  Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.

Authors:  Sven Schmiedl; Rainald Fischer; Luisa Ibanez; Joan Fortuny; Petra Thürmann; Elena Ballarin; Pili Ferrer; Monica Sabaté; Dominik Rottenkolber; Roman Gerlach; Martin Tauscher; Robert Reynolds; Joerg Hasford; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2015-12-23       Impact factor: 4.335

9.  Clinical Outcome Predictive Value of Procalcitonin in Patients Suspected with Infection in the Emergency Department.

Authors:  Pierre Leroux; Sébastien De Ruffi; Laurent Ramont; Marion Gornet; Guillaume Giordano Orsini; Xavier Losset; Lukshe Kanagaratnam; Stéphane Gennai
Journal:  Emerg Med Int       Date:  2021-06-10       Impact factor: 1.112

10.  Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis.

Authors:  Alberto Farina; Federico Moro; Frederick Fasslrinner; Annahita Sedghi; Miluska Bromley; Timo Siepmann
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.